Intellectual Property & Proprietary Rights



Issued US Patents


US #9,233,120

Antibodies or the use of antibodies directed against CCL25 and CCR9 to prevent and treat cancer and cancer cell migration

US #9,249,204

CXCL13-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR5-mediated disorders.

US #9,493,531

CCL18-immunoglobulin fusion polypeptides and conjugates for targeted treatment of PITPNM3-, GPR30-, and CCR8 -mediated disorders.

US #6,153,182

Compositions and doses of lymphotactin given in conjunction with vaccines to provide improved immune response

US #6,479,047

Methods of lymphotactin use as an adjuvant to boost mucosal immune responses to a vaccine antigen

US #7,919,083

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate melanoma growth, migration, and/or invasion.

US #7,964,194

Antibodies or the use of antibodies directed against CXCL10 that mediate inflammation

US #8,097,250

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate melanoma growth, migration, and/or invasion

US #8,231,907

Methods of milling nanoparticles containing a biologically active agent, at least one biopolymer, where coating contains at least one polymer or ligand

US #8,318,170

Antibodies or the use of antibodies directed against CXCL9 and CXCL11 that mediate inflammation

US #8,512,701

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 to prevent and treat cancer and cancer cell migration.

US #8,541,564

Novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders.

US #8,580,261

Antibodies or the use of antibodies directed against CCL25 that mediate inflammation

US #8,563,476

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) as agents against inflammatory disorders

US #8,568,784

Compositions comprising milled nanoparticles containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate

US #8,658,377

Antibodies or the use of antibodies directed against CCL25 and CCR9 to detect cancer and metastasis

US #8,796,422

CCL2-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CCR2-and CCR4-mediated disorders

US #8,962,030

Methods of formulating a pharmaceutical composition using milled nanoparticles of precise size containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate

US #8,987,210

Chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates


Pending US Patent Application

US 15/282,069

CXCL12-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR4-mediated disorders.

US 15/470,215

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of antimicrobials to plants

US 12/967,795

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate leukemia growth, migration, and/or invasion

US 12/967,816

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate carcinoma growth, migration, and/or invasion

US 12/968,659

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate carcinoma growth, migration, and/or invasion

US 12/968,698

Antibodies directed against CXCL13 and CXCR5 that propagate lymphoma growth, migration, and/or invasion

US 13/014,240

Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate lymphoma or myeloma growth, migration, and/or invasion

US 13/014,310

antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate leukemia and myeloma growth, migration, and/or invasion

US 13/104,654

antibodies or the use of antibodies directed against chemokines (CXCL9) that mediate inflammation

US 13/105,335

Antibodies or the use of antibodies directed against chemokines (CCL25 and other CCL chemokines) that mediate inflammation

US 13/233,769

Antibodies or the use of antibodies directed against CXCL16 and CXCR6 to prevent and treat cancer and cancer cell migration

US 13/312,343

Antibodies or the use of antibodies directed against CXCL16 and CXCR6 to detect cancer and metastatic path

US 13/313,705

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 to detect cancer and metastatic path

US 13/535,202

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) for inhibition of inflammation

US 13/569,941

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of cytotoxic drugs to cancer cells


Foreign Patent Applications

AU2003291549

Antibodies or the use of antibodies directed against chemokines that mediate cancer cell migration and growth

AU 2012295366

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of cytotoxic drugs to cancer cells

CN 201180065073.3

Antibodies or the use of antibodies directed against CXCL13 and CXCR5 to detect and treat cancer

CN 201180067113.8

Antibodies or the use of antibodies directed against CCL25 and CCR9 to detect cancer and metastasis

CN 201180067126.5

Antibodies or the use of antibodies directed against CCL25 and CCR9 to prevent and treat cancer

CN 201180067580.0

Antibodies or the use of antibodies directed against CXCL16 and CXCR6 to detect and treat cancer

CN 201280032847.7

Novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders

CN 201280050727

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of cytotoxic drugs to cancer cells

CN 201280075410.1

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) as agents to detect inflammatory disorders

CN 201280075412.0

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) to prevent and treat inflammation

EP 7753470.9

Milling nanoparticles containing a biologically active agent, at least one biopolymer, where coating contains at least one polymer or ligand

EP 11848243.9

antibodies or the use of antibodies directed against CXCL16 and CXCR6 to detect and treat cancer

EP 11848773.5

antibodies or the use of antibodies directed against CCL25 and CCR9 to detect cancer and metastasis

EP 11849217.2

antibodies or the use of antibodies directed against CXCL13 and CXCR5 to detect and treat cancer

EP 11849820.3

Antibodies or the use of antibodies directed against CCL25 and CCR9 to prevent and treat cancer

EP 12782144.3

Novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders

EP 12823626.2

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of cytotoxic drugs to cancer cells

EP 12880044.8

Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) to prevent and treat inflammation

HK 14111652.0

Novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders

HK 151002888.4

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of cytotoxic drugs to cancer cells

JP 2013-544554

antibodies or the use of antibodies directed against CXCL16 and CXCR6 to detect and treat cancer

JP 2013-544565

antibodies or the use of antibodies directed against CXCL13 and CXCR5 to detect and treat cancer

JP 2013-544694

antibodies or the use of antibodies directed against CCL25 and CCR9 to detect cancer and metastasis

JP 2013-544699

antibodies or the use of antibodies directed against CCL25 and CCR9 to prevent and treat cancer

JP P2014-526076

Compositions and methods comprising milled nanoparticles for specific targeting and delivery of cytotoxic drugs to cancer cells

JP P2015-520137

antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) to prevent and treat inflammation